Optimization of the immunosuppressive protocol after lung transplantation

Area of Science:

• Immunology
• Transplantation Medicine
• Pharmacology

Background:

• Tacrolimus (Tac) is a potent immunosuppressant with proven efficacy in organ transplantation.
• Previous positive experiences with Tac in heart transplantation prompted its investigation for lung transplantation.

Purpose of the Study:

• To evaluate the efficacy and safety of Tacrolimus-based immunosuppressive regimens in lung transplant recipients.
• To compare Tac-based therapy with the standard Cyclosporine (CsA)-based regimen.

Main Methods:

• Retrospective analysis of 78 lung transplant patients from 1991-1998.
• Patients were divided into three groups: CsA/Azathioprine (Aza), Tac/Aza, and Tac/Mycophenolate Mofetil (MMF).
• All patients received prednisone; outcomes included acute rejection, infection, survival, renal dysfunction, and glucose metabolism disorders.

Main Results:

• Tac-based regimens significantly reduced acute rejection episodes and refractory acute rejection compared to CsA/Aza.
• Freedom from acute rejection was highest in the Tac-MMF group.
• Actuarial 1- and 3-year survival rates were significantly higher in the Tac groups (93%/71%) versus the CsA group (71%/51%).
• Renal dysfunction prevalence was 18% (CsA/Aza), 13% (Tac/Aza), and 0% (Tac/MMF).
• Incidence of infections and freedom from infection were similar across all groups.

Conclusions:

• Tacrolimus-based immunosuppression is effective in reducing acute rejection and improving survival after lung transplantation.
• Tac therapy demonstrates comparable infection rates to CsA-based therapy.
• A slightly higher incidence of new-onset diabetes mellitus was noted with Tac-based regimens.